Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.9K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.9K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.2K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

9.1K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.1K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

7.9K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Morphologic findings and mutational profiles of myelodysplastic neoplasms with normal versus abnormal karyotype.

Journal of hematopathology·2026
Same author

Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.

Blood·2026
Same author

Molecular taxonomy of MDS/CMML patients influences responses to hypomethylating agents and clinical outcomes.

Leukemia research·2025
Same author

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement.

Blood·2025
Same author

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.

Journal of the National Comprehensive Cancer Network : JNCCN·2025
Same author

Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]).

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2024

Related Experiment Video

Updated: Mar 25, 2026

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

15.6K

Immune checkpoint pathways: perspectives on myeloid malignancies.

Gabriel A Rivera1, Iman Saramipoor Behbahan2, Peter L Greenberg1

  • 1a Department of Medicine, Division of Hematology , Stanford Cancer Institute , Stanford , CA , USA ;

Leukemia & Lymphoma
|February 27, 2016
PubMed
Summary

Cancer immune tolerance allows tumors to survive. Blocking immune checkpoints, which tumor cells use to evade immune responses, shows promise for treating various cancers, including myeloid malignancies like myelodysplastic syndromes.

Keywords:
Immunologic therapyPD-1PD-L1myelodysplastic syndromes

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.9K
Preparation of Myeloid Derived Suppressor Cells MDSC from Naive and Pancreatic Tumor-bearing Mice using Flow Cytometry and Automated Magnetic Activated Cell Sorting AutoMACS
14:15

Preparation of Myeloid Derived Suppressor Cells MDSC from Naive and Pancreatic Tumor-bearing Mice using Flow Cytometry and Automated Magnetic Activated Cell Sorting AutoMACS

Published on: June 18, 2012

26.9K

Related Experiment Videos

Last Updated: Mar 25, 2026

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

15.6K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.9K
Preparation of Myeloid Derived Suppressor Cells MDSC from Naive and Pancreatic Tumor-bearing Mice using Flow Cytometry and Automated Magnetic Activated Cell Sorting AutoMACS
14:15

Preparation of Myeloid Derived Suppressor Cells MDSC from Naive and Pancreatic Tumor-bearing Mice using Flow Cytometry and Automated Magnetic Activated Cell Sorting AutoMACS

Published on: June 18, 2012

26.9K

Area of Science:

  • Oncology
  • Immunology

Background:

  • Tumor cells can evade immune detection through mechanisms like immune tolerance.
  • Immune checkpoints are proteins expressed by tumor cells that inhibit immune cell function, promoting tumor survival.
  • Recent therapeutic strategies targeting immune checkpoints have shown efficacy in solid and lymphoid tumors.

Purpose of the Study:

  • To review recent advances in immune checkpoint biology.
  • To discuss the potential of immune checkpoint inhibitors for treating myeloid malignancies, specifically myelodysplastic syndromes (MDS).

Main Methods:

  • Review of current literature on immune checkpoint biology and therapy.
  • Analysis of clinical trial data for checkpoint inhibitors in various cancers.
  • Focus on the applicability of these therapies to myeloid malignancies.

Main Results:

  • Immune checkpoint blockade has demonstrated therapeutic efficacy in diverse tumor types.
  • Myeloid malignancies, including MDS, exhibit immune dysregulation making them potential candidates for immunotherapy.
  • Checkpoint inhibitors represent a promising therapeutic avenue for patients with myeloid malignancies.

Conclusions:

  • Targeting immune checkpoints is a validated strategy for cancer therapy.
  • Immune checkpoint inhibitors hold significant potential for treating myelodysplastic syndromes and other myeloid malignancies.
  • Further research and clinical trials are warranted to optimize immunotherapy for these hematologic cancers.